Ira Espuny-Camacho, PhD, University of Liège, Liège, Belgium, discusses using hematopoietic stem cells (HSCs) in disease models and clinical therapies. She highlights how human stem cell-based models may yield more accurate data and lead to more efficacious therapies than current animal models. Therapies based on HSCs additionally have many advantages, as they can be easily mass-produced and can differentiate into various cell types such as cardiomyocytes and retinal pigment epithelia for different indications. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).